Skip to main content
TipRanks
Go Ultimate75% OFF

Compare MBX Biosciences, Inc. (MBX) vs. Competitors

240 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
MBXMBX Biosciences, Inc.$55.94$2.78B-18.28132.41%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumMBXUnlock the MBX top-analyst price target with TipRanks Premium
INVAInnoviva$19.03$1.35B7.49-14.28%Strong BuyUnlock the INVA analyst price target with TipRanks PremiumMBX vs INVAUnlock the INVA top-analyst price target with TipRanks Premium
XERSXeris Pharmaceuticals$16.66$3.04B-415.46129.48%Strong BuyUnlock the XERS analyst price target with TipRanks PremiumMBX vs XERSUnlock the XERS top-analyst price target with TipRanks Premium
MLYSMineralys Therapeutics, Inc.$15.33$1.36B-3.52-65.39%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumMBX vs MLYSUnlock the MLYS top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$20.00$1.43B-5.13-42.86%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumMBX vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$13.27$1.72B-4.38-48.96%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumMBX vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
MBXMBX Biosciences, Inc.55.9430.33118.43%
INVAInnoviva19.03-2.94-13.38%
XERSXeris Pharmaceuticals16.669.40129.48%
MLYSMineralys Therapeutics, Inc.15.33-28.93-65.36%
GPCRStructure Therapeutics, Inc. Sponsored ADR20.00-17.44-46.58%
KLRAKailera Therapeutics, Inc.13.27-12.73-48.96%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts